Skip to main content
. Author manuscript; available in PMC: 2008 Apr 1.
Published in final edited form as: Exp Hematol. 2007 Apr;35(4):587–595. doi: 10.1016/j.exphem.2006.12.007

Figure 6.

Figure 6

Effect of Epo on JAK2V617F frequency: MNC from five PV patients (PV#10–14) were used for the expansion of erythroid progenitors as described earlier. At the end of S1 step, the cells were divided into two groups. Half the cells were grown in S2 medium without any Epo (S2-Epo: lane1) while the other half was grown in S2 containing 3units/ml of Epo (S2+Epo: lane2). At the end of S2 step of erythroid expansion, both the groups were grown separately, in complete S3 medium (cells from S2-Epo are labeled as S3 (lane3) and cells from S2+Epo are labeled as S3+Epo: lane4, respectively). JAK2V617F frequency was measured at the end of expansion and expressed as percent change in their JAK2V617F frequency using the granulocyte JAK2V617F at a value of 100. Significance was determined using the students’ t-test. * P<0.05.